Malta - English - Medicines Authority

jubilant pharmaceuticals nv axxes business park, guldensporenpark 22 – block c, 9820 merelbeke, belgium - candesartan cilexetil, hydrochlorothiazide - tablet - candesartan cilexetil 16 mg hydrochlorothiazide 12.5 mg - agents acting on the renin-angiotensin system

Malta - English - Medicines Authority

jubilant pharmaceuticals nv axxes business park, guldensporenpark 22 – block c, 9820 merelbeke, belgium - candesartan cilexetil, hydrochlorothiazide - tablet - candesartan cilexetil 32 mg hydrochlorothiazide 25 mg - agents acting on the renin-angiotensin system

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil 16 mg - candesartan cilexitil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexitil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s j

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet - excipient ingredients: carrageenan; povidone; lactose monohydrate; magnesium stearate; croscarmellose sodium; iron oxide black; titanium dioxide; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; iron oxide red; iron oxide yellow; lactose monohydrate; magnesium stearate; aluminium magnesium silicate; propylene glycol - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 32 mg - tablet - excipient ingredients: carmellose calcium; hyprolose; maize starch; glyceryl monostearate; lactose monohydrate; magnesium stearate; iron oxide yellow - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: magnesium stearate; propylene glycol; iron oxide yellow; lactose monohydrate; carmellose calcium; aluminium magnesium silicate; hyprolose; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: propylene glycol; aluminium magnesium silicate; iron oxide red; lactose monohydrate; carmellose calcium; magnesium stearate; hyprolose; iron oxide yellow - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: hyprolose; iron oxide yellow; maize starch; iron oxide red; glyceryl monostearate; carmellose calcium; lactose monohydrate; magnesium stearate - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil 16 mg - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joi